NEW YORK (GenomeWeb News) - Scienta Health, a Toronto-based health clinic, will offer GeneNews’ colorectal cancer risk-assessment test to its patients, GeneNews said today.
Scienta will offer ColonSentry to its clients as an “optional component” in their annual health assessments, Toronto-based GeneNews said.
Elaine Chin, chief medical officer and co-founder of Scienta Health, said in a statement that ColonSentry “provides a more accurate and reliable basis for recommending colonoscopies than demographic benchmarks or the less sophisticated occult blood stool test.”
Heiner Dreismann, interim CEO and lead director of GeneNews, said that the partnership with Scienta is an example of “one component” of the company’s commercialization strategy for ColonSentry. “In the coming months, we expect to roll out our test in additional regions in Canada and target private health insurers to include our test under their healthcare offerings,” he said.